Multiple Myeloma New Reference: Talquetamab for Relapsed/Refractory Multiple Myeloma Ulas D. Bayraktar, MD 2025-04-07
Pancreatic Cancer New Reference: Neoadjuvant FOLFIRNOX for Pancreatic Cancer Ulas D. Bayraktar, MD 2025-04-07
Colorectal Cancer New Reference: Encorafenib, Cetuximab, Chemotherapy in bRAF Mutant Colorectal Cancer Ulas D. Bayraktar, MD 2025-03-31
Bladder Cancer New Indication: Adjuvant Pembrolizumab for Bladder Cancer Ulas D. Bayraktar, MD 2025-03-31
Non-Small Cell Lung Cancer New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations Ulas D. Bayraktar, MD 2025-03-31
Neuroendocrine Carcinoma New Indication: Cabozantinib for Advanced Neuroendocrine Tumors Ulas D. Bayraktar, MD 2025-03-28
Non-Small Cell Lung Cancer New Drug: Ivonescimab for PD-L1 Positive NSCLC Ulas D. Bayraktar, MD 2025-03-14
Skeletal Sarcoma New Drug: Vimseltinib for Tenosynovial Giant Cell Tumor Ulas D. Bayraktar, MD 2025-03-14
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for Treatment-Naive CLL Ulas D. Bayraktar, MD 2025-03-14
Head and Neck Cancer New Indication: Enfortumab Vedotin for Head and Neck Cancer Ulas D. Bayraktar, MD 2025-03-02
